Oncotarget

Vol 9, No 74

September 21, 2018

View Archive »

Order a Reprint

About The Cover

The cover for issue 74 of Oncotarget features Figure 4, "Treatment interruptions and dose modifications," by Jordan, et al.

Table of Contents

News

It’s a numbers game—density-dependent MMP activity mediates cancer cell migration

It’s a numbers game—density-dependent MMP activity mediates cancer cell migration

https://doi.org/10.18632/oncotarget.26115

Jude M. Phillip, Nahuel Zamponi,  and Madonna P. Phillip
33867-33868
PDF  |  Order a Reprint

Editorial

A 17-gene-expression profile to improve prognosis prediction in childhood acute myeloid leukemia

A 17-gene-expression profile to improve prognosis prediction in childhood acute myeloid leukemia

https://doi.org/10.18632/oncotarget.26116

Nicolas Duployez, Claude Preudhomme,  and Meyling Cheok
33869-33870
PDF  |  Order a Reprint

Research Papers

IRS-2 deubiquitination by USP9X maintains anchorage-independent cell growth via Erk1/2 activation in prostate carcinoma cell line

IRS-2 deubiquitination by USP9X maintains anchorage-independent cell growth via Erk1/2 activation in prostate carcinoma cell line

https://doi.org/10.18632/oncotarget.26049

Haruka Furuta, Hidehito Yoshihara, Toshiaki Fukushima, Yosuke Yoneyama, Akihiro Ito, Claire Worrall, Ada Girnita, Leonard Girnita, Minoru Yoshida, Tomoichiro Asano, Masayuki Komada, Naoyuki Kataoka, Kazuhiro Chida, Fumihiko Hakuno,  and Shin-Ichiro Takahashi
33871-33883
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

The core sequence of PIF competes for insulin/amyloid β in insulin degrading enzyme: potential treatment for Alzheimer’s disease

The core sequence of PIF competes for insulin/amyloid β in insulin degrading enzyme: potential treatment for Alzheimer’s disease

https://doi.org/10.18632/oncotarget.26057

Soren Hayrabedyan, Krassimira Todorova, Marialuigia Spinelli, Eytan R. Barnea,  and Martin Mueller
33884-33895
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-BclxL strategies through Mcl-1 down-regulation

Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-BclxL strategies through Mcl-1 down-regulation

https://doi.org/10.18632/oncotarget.26084

Marie-Laure Bonnefond, Romane Florent, Sophie Lenoir, Bernard Lambert, Edwige Abeilard, Florence Giffard, Marie-Hélène Louis, Nicolas Elie, Mélanie Briand, Denis Vivien, Laurent Poulain, Pascal Gauduchon,  and Monique N’Diaye
33896-33911
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Estrogen receptor-beta is a potential target for triple negative breast cancer treatment

Estrogen receptor-beta is a potential target for triple negative breast cancer treatment

https://doi.org/10.18632/oncotarget.26089

David Austin, Nalo Hamilton, Yahya Elshimali, Richard Pietras, Yanyuan Wu,  and Jaydutt Vadgama
33912-33930
Abstract  |  PDF  |  HTML  |  Order a Reprint

Isolation of cancer cells with augmented spheroid-forming capability using a novel tool equipped with removable filter

Isolation of cancer cells with augmented spheroid-forming capability using a novel tool equipped with removable filter

https://doi.org/10.18632/oncotarget.26092

Emi Fujibayashi, Norikazu Yabuta, Yukihiro Nishikawa, Toshihiro Uchihashi, Daisaku Miura, Kyoko Kurioka, Susumu Tanaka, Mikihiko Kogo,  and Hiroshi Nojima
33931-33946
Abstract  |  PDF  |  HTML  |  Order a Reprint

Hepatitis B virus promotes β-catenin-signalling and disassembly of adherens junctions in a Src kinase dependent fashion

Hepatitis B virus promotes β-catenin-signalling and disassembly of adherens junctions in a Src kinase dependent fashion

https://doi.org/10.18632/oncotarget.26103

Gesa von Olshausen, Maria Quasdorff, Romina Bester, Silke Arzberger, Chunkyu Ko, Maarten van de Klundert, Ke Zhang, Margarete Odenthal, Marc Ringelhan, Carien M. Niessen,  and Ulrike Protzer
33947-33960
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents

Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents

https://doi.org/10.18632/oncotarget.26104

Emma J. Jordan, James Spicer,  and Debashis Sarker
33961-33971
Abstract  |  PDF  |  HTML  |  Order a Reprint

Inhibitory effects of pentoxifylline on inflammation-related tumorigenesis in rat colon

Inhibitory effects of pentoxifylline on inflammation-related tumorigenesis in rat colon

https://doi.org/10.18632/oncotarget.26119

Yohei Shirakami, Takahiro Kochi, Masaya Kubota, Hiroyasu Sakai, Takashi Ibuka, Kazuto Yoshimi, Takashi Kuramoto, Takuji Tanaka, Masahito Shimizu,  and Mitsuru Seishima
33972-33981
Abstract  |  PDF  |  HTML  |  Order a Reprint

Sulforaphane inhibits growth and blocks Wnt/β-catenin signaling of colorectal cancer cells

Sulforaphane inhibits growth and blocks Wnt/β-catenin signaling of colorectal cancer cells

https://doi.org/10.18632/oncotarget.26125

Dominic B. Bernkopf, Gabriele Daum, Martina Brückner,  and Jürgen Behrens
33982-33994
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer

Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer

https://doi.org/10.18632/oncotarget.26129

Dennis Ruder, Vassiliki Papadimitrakopoulou, Kazuhiko Shien, Carmen Behrens, Neda Kalhor, Huiqin Chen, Li Shen, J. Jack Lee, Waun Ki Hong, Ximing Tang, Luc Girard, John D. Minna, Lixia Diao, Jing Wang, Barbara Mino, Pamela Villalobos, Jaime Rodriguez-Canales, Nana E. Hanson, James Sun, Vincent Miller, Joel Greenbowe, Garrett Frampton, Roy S. Herbst, Veera Baladandayuthapani, Ignacio I. Wistuba,  and Julie G. Izzo
33995-34008
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

https://doi.org/10.18632/oncotarget.26131

Laurens E. Franssen, Inger S. Nijhof, Chad C. Bjorklund, Hsiling Chiu, Ruud Doorn, Jeroen van Velzen, Maarten Emmelot, Berris van Kessel, Mark-David Levin, Gerard M.J. Bos, Annemiek Broijl, Saskia K. Klein, Harry R. Koene, Andries C. Bloem, Aart Beeker, Laura M. Faber, Ellen van der Spek, Reinier Raymakers, Pieter Sonneveld, Sonja Zweegman, Henk M. Lokhorst, Anjan Thakurta, Xiaozhong Qian, Tuna Mutis,  and Niels W.C.J. van de Donk
34009-34021
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Clinical Research Papers

The role of different adjuvant therapies in locally advanced gastric adenocarcinoma

The role of different adjuvant therapies in locally advanced gastric adenocarcinoma

https://doi.org/10.18632/oncotarget.26106

Ilaria Benevento, Nadia Bulzonetti, Francesca De Felice, Daniela Musio, Massimo Vergine,  and Vincenzo Tombolini
34022-34029
Abstract  |  PDF  |  HTML  |  Order a Reprint

Corrections

Correction: p53 and metabolism: from mechanism to therapeutics

Correction: p53 and metabolism: from mechanism to therapeutics

https://doi.org/10.18632/oncotarget.26181

Fernando M. Simabuco, Mirian G. Morale, Isadora C.B. Pavan, Ana P. Morelli, Fernando R. Silva,  and Rodrigo E. Tamura
34030-34030
Correction  |  PDF


Copyright © 2018 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC